Last reviewed · How we verify
NCT05215470
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
Phase 2 trial testing Nivolumab in Renal Cancer Metastatic in 100 participants. Participants enrolled and being followed up; not accepting new ones.
30 November 2024
Quick facts
| Lead sponsor | Hospital das Clínicas de Ribeirão Preto |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 18 January 2022 |
| Primary completion | 30 November 2024 |
| Estimated completion | 30 November 2026 |
| Sites | 1 location across Brazil |
Drugs / interventions tested
- Nivolumab (nivolumab) — full drug profile →
- Ipilimumab — full drug profile →
Conditions studied
- Renal Cancer Metastatic — all drugs for Renal Cancer Metastatic →
Sponsor
Hospital das Clínicas de Ribeirão Preto
Who can join
18 and older, any sex, with Renal Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is studying the joint contribution and interactions of germline variants and somatic mutations and their impact on Renal Cell Carcinoma (RCC) development and treatment (immunotherapy).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the "all-around warrior" in immunotherapy.
Liu Q, Guan Y, Li S. · · 2024 · cited 50× · PMID 39223527 · DOI 10.1186/s12943-024-02095-8
Verify or expand the search:
- PubMed search for NCT05215470
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Nivolumab
Trials testing the same drug.
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07444619 — A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young A · Phase 1 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
- NCT07420439 — Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease · Phase 2 · not yet recruiting
- NCT07510334 — VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma · Phase 2 · not yet recruiting
Other recruiting trials for Renal Cancer Metastatic
Currently open trials in the same condition.
- NCT06889649 — SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC · Phase 2 · recruiting
Other Hospital das Clínicas de Ribeirão Preto trials
Trials by the same sponsor.
- NCT07044830 — Obstructive Sleep Apnea Treatment From Acute to Chronic Phase of Stroke · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05215470 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital das Clínicas de Ribeirão Preto
- Last refreshed: 3 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05215470.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing